Optos introduces new retinal scanning device
This article was originally published in Clinica
Executive Summary
Eye imaging firm Optos is launching a new ultra-wide field retinal imaging device, 200Tx, worldwide. The product is the first to incorporate auto-fluorescence technology to help detect changes in the retinal pigment epithelium, a pigmented cell layer just outside the retina. This could aid the diagnosis and management of age-related macular degeneration (AMD). Previously, the disorder was not thought to affect peripheral vision, but a study using 200Tx reported in September that 76% of eyes in 122 AMD patients had peripheral abnormalities, and that adding auto-fluorescence improved the detection of AMD (www.clinica.co.uk, 3 September 2010). Dunfermline, UK-based Optos exhibited the new device at the annual meeting of the American Academy of Ophthalmology, being held in Chicago, Illinois on 16-19 October, and plans to launch it commercially in the first quarter of 2011.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.